The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a Valproate National Patient Safety Alert in advance of new regulatory measure being introduced from January 2024.
The Council of the GPhC will be meeting on Thursday 9 November.
Please contact our Council secretary by 4pm on Wednesday 8 November 2023, if you would like to attend the meeting.
We are very sorry for the technical issues registrants have been experiencing with My GPhC. We are working to resolve any outstanding problems as quickly as possible. We will provide a further update on the situation tomorrow. In the meantime, we have extended the deadline for those due to submit their renewal or revalidation by 31 October 2023 to 11.59pm on Tuesday 7 November 2023.
myGPhC is currently up and running, but you may experience delays. We are still monitoring the situation and trying to fix the issue as a priority. We apologise for the inconvenience caused and will continue to provide updates.
The GPhC has today published an initial analysis of diversity data of professionals involved in its Fitness to Practise process in 2021/22, looking specifically at concerns received and investigated, statutory outcomes of closed concerns and progression through the process.
Medicines containing valproate must now be sold or supplied in the manufacturer’s original outer packaging, with warnings about the risks of taking the medication during pregnancy
The GPhC has joined a new group, led by the Royal Pharmaceutical Society (RPS) to address the differential attainment and awarding gap experienced by black pharmacy students and Foundation Trainees
